Bispecific anti-IGF-1R and anti-ErbB3 antibodies
AssigneeMerrimack Pharmaceuticals, Inc.
InventorsJason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
Life of this patent
Estimating the term…
Abstract
Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
Claims15
Polyvalent bispecific antibody P4−G1−M1.3 having two pairs of polypeptide chains, each pair of said two pairs comprising a heavy chain joined to a light chain by at least one heavy-light chain bond, wherein each light chain comprises the amino acid sequence set forth in SEQ ID NO:204 and each heavy chain comprises the amino acid sequence set forth in SEQ ID NO:226.
Polyvalent bispecific antibody P4−G1−C8 having two pairs of polypeptide chains, each pair of said two pairs comprising a heavy chain joined to a light chain by at least one heavy-light chain bond, wherein each light chain comprises the amino acid sequence set forth in SEQ ID NO:204 and each heavy chain comprises the amino acid sequence set forth in SEQ ID NO:222.
Polyvalent bispecific antibody M7−G1−M78 having two pairs of polypeptide chains, each pair of said two pairs comprising a heavy chain joined to a light chain by at least one heavy-light chain bond, wherein each light chain comprises the amino acid sequence set forth in SEQ ID NO:262 and each heavy chain comprises the amino acid sequence set forth in SEQ ID NO:284.
Dependencies are inferred from the claim text.